Assessing cognition and function in Alzheimer's disease clinical trials

Do we have the right tools?

Peter J. Snyder, Kristin Kahle-Wrobleski, Stephen Brannan, David S. Miller, Rachel J. Schindler, Susan Desanti, J. Michael Ryan, Glenn Morrison, Michael Grundman, Julie Chandler, Richard John Caselli, Maria Isaac, Lisa Bain, Maria C. Carrillo

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Several lines of evidence from Alzheimer's disease (AD) research continue to support the notion that the biological changes associated with AD are occurring possibly several decades before an individual will experience the cognitive and functional changes associated with the disease. The National Institute on Aging - Alzheimer's Association revised criteria for AD provided a framework for this new thinking. As a result of this growing understanding, several research efforts have launched or will be launching large secondary prevention trials in AD. These and other efforts have clearly demonstrated a need for better measures of cognitive and functional change in people with the earliest changes associated with AD. Recent draft guidance from the US Food and Drug Administration further elevated the importance of cognitive and functional assessments in early stage clinical trials by proposing that even in the pre-symptomatic stages of the disease, approval will be contingent on demonstrating clinical meaningfulness. The Alzheimer's Association's Research Roundtable addressed these issues at its fall meeting October 28-29, 2013, in Washington, D.C. The focus of the discussion included the need for improved cognitive and functional outcome measures for clinical of participants with preclinical AD and those diagnosed with Mild Cognitive Impairment due to AD.

Original languageEnglish (US)
Pages (from-to)853-860
Number of pages8
JournalAlzheimer's and Dementia
Volume10
Issue number6
DOIs
StatePublished - Nov 1 2014

Fingerprint

Cognition
Alzheimer Disease
Clinical Trials
National Institute on Aging (U.S.)
Research
Asymptomatic Diseases
United States Food and Drug Administration
Secondary Prevention
Outcome Assessment (Health Care)

Keywords

  • Alzheimer's disease
  • Biomarkers
  • Diagnostic criteria

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Epidemiology
  • Health Policy

Cite this

Snyder, P. J., Kahle-Wrobleski, K., Brannan, S., Miller, D. S., Schindler, R. J., Desanti, S., ... Carrillo, M. C. (2014). Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools? Alzheimer's and Dementia, 10(6), 853-860. https://doi.org/10.1016/j.jalz.2014.07.158

Assessing cognition and function in Alzheimer's disease clinical trials : Do we have the right tools? / Snyder, Peter J.; Kahle-Wrobleski, Kristin; Brannan, Stephen; Miller, David S.; Schindler, Rachel J.; Desanti, Susan; Ryan, J. Michael; Morrison, Glenn; Grundman, Michael; Chandler, Julie; Caselli, Richard John; Isaac, Maria; Bain, Lisa; Carrillo, Maria C.

In: Alzheimer's and Dementia, Vol. 10, No. 6, 01.11.2014, p. 853-860.

Research output: Contribution to journalArticle

Snyder, PJ, Kahle-Wrobleski, K, Brannan, S, Miller, DS, Schindler, RJ, Desanti, S, Ryan, JM, Morrison, G, Grundman, M, Chandler, J, Caselli, RJ, Isaac, M, Bain, L & Carrillo, MC 2014, 'Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools?', Alzheimer's and Dementia, vol. 10, no. 6, pp. 853-860. https://doi.org/10.1016/j.jalz.2014.07.158
Snyder PJ, Kahle-Wrobleski K, Brannan S, Miller DS, Schindler RJ, Desanti S et al. Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools? Alzheimer's and Dementia. 2014 Nov 1;10(6):853-860. https://doi.org/10.1016/j.jalz.2014.07.158
Snyder, Peter J. ; Kahle-Wrobleski, Kristin ; Brannan, Stephen ; Miller, David S. ; Schindler, Rachel J. ; Desanti, Susan ; Ryan, J. Michael ; Morrison, Glenn ; Grundman, Michael ; Chandler, Julie ; Caselli, Richard John ; Isaac, Maria ; Bain, Lisa ; Carrillo, Maria C. / Assessing cognition and function in Alzheimer's disease clinical trials : Do we have the right tools?. In: Alzheimer's and Dementia. 2014 ; Vol. 10, No. 6. pp. 853-860.
@article{b4f6360386c04ed2a70d0a6255ea9690,
title = "Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools?",
abstract = "Several lines of evidence from Alzheimer's disease (AD) research continue to support the notion that the biological changes associated with AD are occurring possibly several decades before an individual will experience the cognitive and functional changes associated with the disease. The National Institute on Aging - Alzheimer's Association revised criteria for AD provided a framework for this new thinking. As a result of this growing understanding, several research efforts have launched or will be launching large secondary prevention trials in AD. These and other efforts have clearly demonstrated a need for better measures of cognitive and functional change in people with the earliest changes associated with AD. Recent draft guidance from the US Food and Drug Administration further elevated the importance of cognitive and functional assessments in early stage clinical trials by proposing that even in the pre-symptomatic stages of the disease, approval will be contingent on demonstrating clinical meaningfulness. The Alzheimer's Association's Research Roundtable addressed these issues at its fall meeting October 28-29, 2013, in Washington, D.C. The focus of the discussion included the need for improved cognitive and functional outcome measures for clinical of participants with preclinical AD and those diagnosed with Mild Cognitive Impairment due to AD.",
keywords = "Alzheimer's disease, Biomarkers, Diagnostic criteria",
author = "Snyder, {Peter J.} and Kristin Kahle-Wrobleski and Stephen Brannan and Miller, {David S.} and Schindler, {Rachel J.} and Susan Desanti and Ryan, {J. Michael} and Glenn Morrison and Michael Grundman and Julie Chandler and Caselli, {Richard John} and Maria Isaac and Lisa Bain and Carrillo, {Maria C.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.jalz.2014.07.158",
language = "English (US)",
volume = "10",
pages = "853--860",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Assessing cognition and function in Alzheimer's disease clinical trials

T2 - Do we have the right tools?

AU - Snyder, Peter J.

AU - Kahle-Wrobleski, Kristin

AU - Brannan, Stephen

AU - Miller, David S.

AU - Schindler, Rachel J.

AU - Desanti, Susan

AU - Ryan, J. Michael

AU - Morrison, Glenn

AU - Grundman, Michael

AU - Chandler, Julie

AU - Caselli, Richard John

AU - Isaac, Maria

AU - Bain, Lisa

AU - Carrillo, Maria C.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Several lines of evidence from Alzheimer's disease (AD) research continue to support the notion that the biological changes associated with AD are occurring possibly several decades before an individual will experience the cognitive and functional changes associated with the disease. The National Institute on Aging - Alzheimer's Association revised criteria for AD provided a framework for this new thinking. As a result of this growing understanding, several research efforts have launched or will be launching large secondary prevention trials in AD. These and other efforts have clearly demonstrated a need for better measures of cognitive and functional change in people with the earliest changes associated with AD. Recent draft guidance from the US Food and Drug Administration further elevated the importance of cognitive and functional assessments in early stage clinical trials by proposing that even in the pre-symptomatic stages of the disease, approval will be contingent on demonstrating clinical meaningfulness. The Alzheimer's Association's Research Roundtable addressed these issues at its fall meeting October 28-29, 2013, in Washington, D.C. The focus of the discussion included the need for improved cognitive and functional outcome measures for clinical of participants with preclinical AD and those diagnosed with Mild Cognitive Impairment due to AD.

AB - Several lines of evidence from Alzheimer's disease (AD) research continue to support the notion that the biological changes associated with AD are occurring possibly several decades before an individual will experience the cognitive and functional changes associated with the disease. The National Institute on Aging - Alzheimer's Association revised criteria for AD provided a framework for this new thinking. As a result of this growing understanding, several research efforts have launched or will be launching large secondary prevention trials in AD. These and other efforts have clearly demonstrated a need for better measures of cognitive and functional change in people with the earliest changes associated with AD. Recent draft guidance from the US Food and Drug Administration further elevated the importance of cognitive and functional assessments in early stage clinical trials by proposing that even in the pre-symptomatic stages of the disease, approval will be contingent on demonstrating clinical meaningfulness. The Alzheimer's Association's Research Roundtable addressed these issues at its fall meeting October 28-29, 2013, in Washington, D.C. The focus of the discussion included the need for improved cognitive and functional outcome measures for clinical of participants with preclinical AD and those diagnosed with Mild Cognitive Impairment due to AD.

KW - Alzheimer's disease

KW - Biomarkers

KW - Diagnostic criteria

UR - http://www.scopus.com/inward/record.url?scp=84927161835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927161835&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2014.07.158

DO - 10.1016/j.jalz.2014.07.158

M3 - Article

VL - 10

SP - 853

EP - 860

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 6

ER -